Latham & Watkins advised Seres Therapeutics, while Mayer Brown represented Société des Produits Nestlé on the deal. Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised scPharmaceuticals on the deal. scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
You must be a Standard 1 Year member to access this content.
Latham & Watkins is advising Rhythm Pharmaceuticals on the transaction, and Ropes & Gray is advising Perceptive Advisors LLC. Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (Rhythm), a commercial-stage...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and...
You must be a Standard 1 Year member to access this content.
Latham & Watkins, Wachtell, Lipton, Rosen & Katz, Arnold & Porter, Ropes & Gray, Hogan Lovells, Robinson+Cole, Richards, Layton & Finger, P.A., Arnold & Porter Kaye...
You must be a Standard 1 Year member to access this content.
Covington represented UCB, while Latham & Watkins represented Zogenix on the deal. Fried Frank acted as counsel to BofA Securities and SVB Leerink as financial advisors to...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented P3 Health Partners in the transaction. P3 Health Partners, a patient-centered and physician-led population health management company, has closed its previously announced business combination...
You must be a Standard 1 Year member to access this content.
Schiff Hardin advised BK Medical on the deal. Latham & Watkins represented Altaris Capital. GE Healthcare has entered into an agreement to acquire BK Medical, a...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Sight Sciences, Inc. in the offering, while Davis Polk advised the representatives of the several underwriters. Sight Sciences, Inc. executed its initial public...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented the initial purchasers in the offering. Haemonetics Corporation (NYSE: HAE) priced its offering of US$435 million aggregate principal amount of 0% Convertible...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented SQZ Biotechnologies Company in the transaction. SQZ Biotechnologies Company (NYSE: SQZ) (SQZ), a cell therapy company developing novel treatments for multiple...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented the underwriters in the offering. NANO-X IMAGING LTD (NASDAQ: NNOX), an innovative medical imaging technology company, has announced that it has...
You must be a Standard 1 Year member to access this content.
